We design matter in the latent space of possibility.

Why Converge Materials

We make high-purity materials and bio-enabled molecules on a learning loop that gets faster with every experiment. Here is the case, in one page.

We make the materials at the edge of what your process can tolerate, and we get faster at it with every experiment.

The problem

Advanced industries are running out of margin for error. Semiconductor chemicals that were once fine at parts-per-billion contamination now need parts-per-trillion for critical elements. Battery electrolytes live or die on trace water and acid. Pharmaceutical routes still lean on hazardous steps and precious metals, and new-chemical approvals in the US routinely take longer than the statutory 90 days.

Meanwhile, the companies that set out to fix this by "programming biology" have hit the wall between the lab and the plant.

What we make

• High-purity solvents, etchants, precursors and intermediates for semiconductor, energy-storage and pharmaceutical customers
• Custom-synthesized molecules and formulations built to your specification
• Bio-enabled materials: engineered enzymes, biocatalytic steps and bio-based chemicals
• Toll processing of your materials through our equipment
• Licensed process technology for partners who want to manufacture themselves

How we are different

One loop, three disciplines. Chemistry, biology and AI run together: our models propose, automated systems build, our analytics measure, and results retrain the models. Each cycle is faster and better informed than the last.

Proprietary data. Our advantage comes from our own experiments, including failures, not from public datasets everyone shares. Every route is designed for scale from the first experiment, with safety, quality systems and regulatory strategy built into the product.

Honest about the technology. We add autonomy in stages, validate models prospectively, and control any model used in regulated production. We would rather be reliably useful than loudly ambitious.

Where we are

Privately held, founded 2023. We operate a 30,000-square-foot pilot facility outside Boston with fermentation, purification and analytical suites under one roof, plus a dedicated computational team. An electronic-grade etchant line is in qualification with two semiconductor customers; a biocatalytic step for a chiral pharmaceutical intermediate is in active development with a specialty pharma partner. Next: scaling our pilot etchant line to production volumes in 2027, and opening toll-processing capacity for a third industry vertical.

The Converge Materials Loop: A Materials Company That Gets Smarter With Every Experiment

Chemistry, biology and AI in one closed loop. Why it makes us faster today, and why the advantage compounds.

Most companies in our space are strong at one thing. Chemical firms perfect reactions. Biotech firms perfect strains. Software firms perfect models. Converge Materials runs all three in a single loop.

How the loop works

1. Design. Our models and scientists propose candidates: molecules, enzymes, pathways, formulations, process conditions.
2. Build. Automated systems make them, by chemical synthesis, biological construction or hybrid routes.
3. Test. Integrated analytics measure the result. Data flows straight into our platform.
4. Learn. Results update the models. The next round starts smarter.

Then we do it again. And again.

Why the loop wins

Proprietary data. Public datasets are shared with every competitor. Ours comes from our own instruments, on real chemistry, in real conditions, including what did not work.

A flywheel, not a project. Better models choose better experiments. Better experiments produce better data. Better data trains better models. Every project we complete makes the next one faster.

Proof points

• Loop cycle time: a full design-build-test-learn cycle now runs in under 9 days on our automated lines, down from roughly 6 weeks when the platform first came online.
• Experiments completed: more than 40,000 automated experiments have run through the loop to date.
• Customer outcome: a battery-materials partner cut electrolyte-additive development from a projected 14 months to under 5.

AI That Chooses the Next Experiment: How Converge Materials Finds Better Materials, Faster

Our models propose candidates, predict how far to trust themselves, and pick the experiments that teach us most, then get better with every result.

Experiments are the expensive part of materials development. Our AI exists to make sure we run fewer of them, and that each one counts.

What our AI does

Proposes. Generative and predictive models suggest candidate molecules, enzymes, formulations and process conditions aimed at your performance target: purity, yield, stability, cost, or all four.

Predicts. Graph and geometry-aware models estimate properties and reaction outcomes, and machine-learned atomic potentials approximate expensive quantum calculations at a fraction of the cost.

Chooses. Active learning and Bayesian optimization pick the next experiments to run, balancing exploration of the unknown with improvement of what already works.

Says when it does not know. Every prediction that triggers a physical experiment carries an uncertainty estimate. If the model is out of its depth, we test before we trust.

Proof points

• Models in use: an active-learning model for reaction-condition optimization, a graph neural network for impurity and byproduct prediction, and machine-learned potentials for formulation stability.
• Prospective validation: in blinded trials, our top-5 predicted conditions have included the eventual best-performing condition in 88 percent of campaigns.
• Experiment savings: a chiral intermediate program reached target purity in 30 experiments, against a projected 200 for a conventional screen.

Digital First: We Simulate Your Process Before We Build It

Quantum chemistry, molecular simulation and process modeling let us de-risk your material on a computer, quote with confidence and reach the right route faster.

Every physical experiment costs time and material. So before we run yours, we run it in silico.

What that means for your project

Route scouting in days. Computational chemistry screens reaction pathways and catalysts before anyone touches a flask, so we start at the promising end of the design space.

Fewer failed scale-ups. Reaction-kinetics and heat-and-mass-transfer models show us where a process will run hot, mix poorly or accumulate impurities, before a pilot run has to teach us the expensive way.

Quotes grounded in real economics. We build a techno-economic model before committing to a route: cost per kilogram at different volumes, which step dominates cost, and how sensitive the answer is to yield, feedstock price and purity target.

Design for your plant or ours. Flowsheet and equipment models let us size equipment, estimate utilities and plan for continuous processing where it pays.

Proof points

• Route screened, then confirmed: a hydrogenation route was screened computationally before any bench work; the first physical run landed within 4 percent of the predicted yield.
• Scale-up problem avoided: heat-and-mass-transfer modeling flagged a hot spot in a proposed reactor design before it was built.
• A cost model showed a biocatalytic step became cheaper than the conventional route past roughly 200 kilograms a year.

The Platform Behind Every Batch: Automation, Data and Traceability You Can Audit

Every experiment and every lot at Converge Materials runs through one connected data and automation platform, which means faster development for you and total traceability for your auditors.

Most suppliers sell you a material. We sell you a material and the complete record of how it was made. Behind every Converge Materials product is a connected platform that captures every experiment, every instrument reading and every process parameter, and makes them searchable, comparable and reusable.

What the platform does for you

Faster development. Protocols run as machine-readable workflows on automated equipment, so experiments run in parallel and around the clock.

Full lot traceability. Raw material lot, process conditions, analytical results and packaging record are linked. When a customer asks what happened to a specific container, we can show them.

Consistency you can measure. Because data is captured at the source rather than transcribed, lot-to-lot variation shows up in numbers, not anecdotes.

Confidentiality by design. Your data and process information are isolated by access controls and audit logs. Our control systems are segmented from general IT.

Proof points

• Instruments live: 14 automated reactor modules, 3 parallel fermentation trains and 6 analytical instruments are integrated directly into the platform.
• Data captured: more than 3 million data points across 40,000-plus experiments, all linked to sample, protocol and lot.
• Traceability demo available on request: we can walk your team through a real lot from raw material to shipped container.

What We Make for Semiconductors, Batteries, Pharma and Advanced Materials

Our product and service lines, organized by the industry you work in and the failure modes you cannot afford.

Every demanding industry defines quality differently. We start from your failure modes and work backward to what we make.

Semiconductor manufacturing

Electronic-grade solvents, etchants and process chemicals, and precursors for deposition and processing — with contamination controlled at parts-per-billion to parts-per-trillion, layered purification, trace-element analytics, full lot traceability and change-control discipline built for supplier audits.

Batteries and energy storage

Electrolyte materials, specialty solvents and additives, and cathode precursors — with moisture-controlled handling, safe processing of fluorinated materials, and AI-guided discovery of additives and formulations.

Pharmaceuticals

Intermediates, chiral building blocks, custom-synthesized molecules and process development for APIs, plus engineered enzymes and biocatalytic steps — with continuous processing where it improves control, and a quality system built for the way pharma buys.

Advanced coatings, aerospace and sustainable chemicals

Functional additives, specialty monomers, custom formulations and high-performance feedstocks made to demanding specifications, plus bio-derived and enzyme-enabled materials that replace hazardous or petrochemical routes where economics and regulation support it.

Proof points

• Primary line: our electronic-grade etchant line supplies two active qualification programs.
• In qualification with one North American semiconductor fab and one European battery-cell maker; a biocatalytic intermediate program is in development with a specialty pharma partner.
• Capacity: pilot batches up to 200 kg; typical lead time 6 to 10 weeks for an existing product line.

Ultra-High-Purity Materials, Made to Your Specification

Electronic-grade solvents, etchants and precursors, custom-synthesized molecules and toll processing, purified and verified to the level your process demands.

Your process does not care what grade the label says. It cares what is actually in the bottle.

At Converge Materials, we make the materials that sit at the edge of what your process can tolerate: high-purity solvents, etchants and precursors, custom-synthesized intermediates, and finished formulations built to your specification. We purify them, we verify them, and we deliver them with the data to prove it.

The bar keeps rising. So do we.

Two decades ago, ten parts per billion of metal contamination was acceptable for many semiconductor process chemicals. Today, critical chemicals are expected at 100 parts per trillion per element, and some at ten. Our purification and analytical capability is built around that trajectory, not around last decade's specification.

Why customers choose us

We see what others miss. Our analytical laboratory, built around trace-element and organic analysis, is part of the product, not an afterthought. Where conventional purification hits a ceiling, we combine complementary techniques rather than pushing one step harder — and every route is designed with the plant in mind from the first experiment.

Proof points

• Purity achieved: sub-10 parts-per-trillion across 12 critical elements in our flagship etchant line, with full analytical documentation per lot.
• Capacity: 200-liter pilot reactors today, with a 2,000-liter production train planned for 2027.
• Qualification: first samples shipped to two semiconductor customers; one program has advanced to extended reliability testing.

Bio-Made Molecules: Greener Routes to Materials Chemistry Struggles to Make

Engineered enzymes, biocatalytic steps and bio-based routes that cut waste, remove hazardous steps and reach molecules conventional chemistry finds hard.

Some molecules are hard to make the old way: they need a precious metal, extreme pressure, a wasteful purification, or protective-group gymnastics. We make them the smarter way. We engineer the biology.

What we make with biology

• Biocatalytic steps for chemical processes: enzymes engineered to perform the difficult transformation, slotted into a hybrid route.
• Chiral and specialty intermediates: selective, mild and clean, for pharmaceutical and specialty customers.
• Bio-based chemicals: fermentation-derived materials that can displace petrochemical routes.
• Custom enzymes and engineered strains for partners who need a biological component built for their process.

The proof that this works

The best-known example in industry is the sitagliptin story: an evolved enzyme replaced a rhodium-catalyzed high-pressure hydrogenation, removing the metals, raising productivity by 56 percent in existing equipment, increasing yield and cutting waste. That is the playbook we run: find the step that costs the most, engineer the catalyst that removes it, and prove the economics — with fermentation and downstream purification designed together, and purity and containment built in from day one.

Proof points

• Three active enzyme-engineering programs, including a biocatalytic route for a chiral pharmaceutical intermediate that has cleared bench-scale proof of concept.
• Three parallel 50-liter fermentation trains with integrated downstream purification, scaling to 500 liters in 2027.
• An active development partnership with a specialty pharma customer to replace a metal-catalyzed hydrogenation step with an engineered enzyme.

Built to Be Qualified: Safety, Quality and Compliance Are Part of the Product

Buyers in semiconductors, batteries and pharma choose suppliers that are hard to surprise. Here is how Converge Materials is built to earn that trust from day one.

Fabs, cell makers and drug developers do not buy chemistry. They buy confidence: that the material will be right, that the supplier will tell them before anything changes, and that the plant will still be running next year. We build Converge Materials around that confidence.

Safety is how we design, not what we add

• Structured hazard review at every scale, from first bench work through pilot to production.
• Reactive-chemistry screening before scale-up, so we know a process's limits before we test them.
• Management of change for equipment, chemistry, procedures and roles.
• Independent safeguards on anything software controls — automation never relies on a model behaving well to keep people and product safe.
• A reporting culture where a near miss is a contribution, not a confession.

Quality and regulatory strategy

Different customers require different frameworks, and we build to them: change-control and analytical rigor for semiconductor audits, cGMP-aligned documentation and data integrity for pharma, and the quality discipline automotive and battery supply chains require. For novel substances we treat regulatory time as a schedule item and plan it as one. Any model used in a regulated step is frozen, versioned and change-controlled, so you always know exactly what produced your material.

Proof points

• ISO 9001 certified; working toward ISO 14001 and cGMP-aligned practices for pharmaceutical customers.
• Zero lost-time incidents since founding, with structured HAZOP review at every scale-up.
• Pilot facility fully permitted for chemical and biological processing; production-scale permitting underway alongside our 2027 capacity expansion.

Five Ways to Work With Converge Materials

Supply, custom synthesis, toll processing, development partnerships and licensing: the commercial models we offer, and the discipline behind each.

You have a specification, a bottleneck or a molecule nobody can make at the price you need. Here is how we can help, and how we make sure it pays off for both of us.

1. Specialty materials supply. High-purity materials and formulations to your specification, supplied on agreed volumes with full traceability and advance notice of any process change.
2. Custom synthesis and development. Send us the molecule, the purity, the volume and the timeline. We design the route, prove it, scale it and deliver — designed for manufacturability from the first experiment.
3. Toll processing. Bring your feedstock. We run it through our purification and processing equipment with strict segregation, confidentiality, cleaning validation and complete documentation.
4. Joint development partnerships. For programs where the goal is a new material or process, formed around defined milestones with clear agreements up front on who owns what data.
5. Technology licensing. Once a process is proven, we license process and platform technology to partners who want to make it themselves.

How we protect your interests

Your data and process information stay yours — ownership is settled in writing at the start. We plan for long qualification cycles with agreed acceptance criteria, we map the regulatory path with you early, and we say yes to projects we can deliver at scale, and no to the ones we cannot.

Proof points

• A battery-materials manufacturer runs electrolyte purification through our toll-processing line under a multi-year agreement.
• Typical time from first call to sample: 6 to 10 weeks for an existing product line.
• Pilot capacity currently open for 2 to 3 new development programs per quarter.

Join Converge Materials: Where Chemists, Biologists and Machine-Learning Scientists Build the Same Thing

We are building materials, molecules and the platform behind them, and we need people who work across boundaries.

Most companies put chemistry, biology and software in different buildings, with different goals and different clocks. We put them on one team, working on one loop, making real materials for demanding customers. If you have ever felt that the most interesting problems live between your discipline and the one next door, this is the place.

What you would work on

• Making ultra-high-purity materials for semiconductor, energy-storage and pharmaceutical customers, with purification, trace analytics and scale-up in your hands.
• Engineering enzymes and bio-based routes that replace hazardous or wasteful chemistry.
• Building the platform: data infrastructure, lab automation, model operations and the tools our scientists use every day.
• Teaching models to choose experiments, and finding out when they are right.
• Taking a process from bench to pilot to production, with safety and quality designed in.

Open roles

• Senior Process Chemist — Purification & Scale-Up: own layered purification strategy for our etchant line, from pilot batches through production trains.
• Computational Chemist — Active Learning & Molecular Design: build the models that choose our next experiment, and keep them honest against prospective results.
• Bioprocess Engineer — Fermentation & Downstream: design fermentation and downstream purification together for our enzyme and bio-based chemical programs.

Don't see your role? Tell us what you would build.